Table 1.
Study design of DP6-001 clinical trial
| Group | DNA prime phase
|
Protein boost phase
|
||||||
|---|---|---|---|---|---|---|---|---|
| Plasmids (6) | Dose (mg) | Route | Time (weeks) | Proteins (5) | Dose (mg) | Route | Time (weeks) | |
| A (n = 10) | gp120 (A, B, Bal, C, E) + Gag (C) | 1.2 | ID | 0, 4, 12 | gp120 (A, B, Bal, C, E) | 0.375 | IM | 20, 28 |
| B (n = 11) | gp120 (A, B, Bal, C, E) + Gag (C) | 1.2 | IM | 0, 4, 12 | gp120 (A, B, Bal, C, E) | 0.375 | IM | 20, 28 |
| C (n = 6) | gp120 (A, B, Bal, C, E) + Gag (C) | 7.2 | IM | 0, 4, 12 | gp120 (A, B, Bal, C, E) | 0.375 | IM | 20 |